Tags Archive Navigation
icon
-
Media ReleaseLeqvio®* (inclisiran) reduced LDL-C in people who are overweight or obese
-
Media ReleaseNovartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)
-
Media ReleaseNew data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
-
Media ReleaseNovartis receives priority review by US FDA and filing acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma
-
Media ReleaseNovartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
-
Media ReleaseNovartis réalise de solides résultats au 3e trimestre, avec une forte croissance d’Innovative Medicines, et annonce un examen stratégique de Sandoz
-
Media ReleaseNovartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz an
-
Media ReleaseNovartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
-
Media ReleasePositive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine
-
Media ReleaseNovartis announces NEJM publication of positive Phase III REACH3 data for Jakavi in chronic GvHD
-
Media ReleaseNovartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA
-
Media ReleaseNovartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 15
- › Next page